Although this year is looking a little better than last for med-tech stocks, it's still largely a revenue growth-driven phenomenon. To that end, AngioDynamics' (ANGO) unimpressive growth has pushed it towards being an afterthought for many investors. While this story is going to take time to develop, patient investors might like what they see here in terms of value for money.
No Fast Turnaround In Q3
AngioDynamics has a fairly stable business, which is fine when times are good but not so helpful when procedure volumes are weak. Reported revenue dropped nearly 6% this past quarter, as a nearly 10% decline in U.S. sales offset good growth in its small overseas business.
Please continue here:
AngioDynamics Quietly Getting Interesting
No comments:
Post a Comment